Authorisation granted by the President of the PAA to Urtica for the storage of radioactive sources and waste
Obtaining authorisation from the President of the National Atomic Energy Agency expands Urtica’s storage and logistics capabilities in the field of radiopharmacy and nuclear medicine, and enables the storage of radioactive sources and waste to the extent and under the conditions specified in the administrative decision.
In this article, you will learn:
- What does the PAA Chairman’s authorisation for Urtica cover?
- how it is developing the company’s warehousing and logistics facilities
- What is the significance of procedures and radiation protection?
- what these new opportunities mean for collaboration in the field of radiopharmacy
Formal notice
Licence for the storage of radioactive sources and waste
Urtica Sp. z o.o. holds a licence from the President of the National Atomic Energy Agency to store radioactive sources and waste.
The licence was issued by the President of the National Atomic Energy Agency pursuant to the provisions of the Act of 29 November 2000 – the Atomic Energy Act, which regulates activities involving exposure to ionising radiation, including the storage of radioactive sources and waste.
Warehousing and logistics
Infrastructure development for areas requiring specialised solutions
The authorisation granted by the President of the PAA enables Urtica to carry out activities relating to the storage of radioactive sources and waste within its own infrastructure, to the extent and under the conditions specified in the administrative decision.
In the context of a pharmaceutical wholesaler’s operations, this means developing warehousing and logistics facilities in areas where there are specific regulatory requirements arising from legislation on ionising radiation.
An expert’s view
“Obtaining authorisation from the President of the PAA strengthens Urtica’s warehousing and logistics capabilities in areas requiring specialised and bespoke solutions. This is a major step forward in the development of infrastructure to meet the needs of radiopharmacy and nuclear medicine.”
Radiopharmacy and nuclear medicine
Quality and consistency of procedures
The field of radiopharmacy and the activities of nuclear medicine units involve heightened organisational and procedural requirements. The Atomic Energy Act imposes an obligation on entities carrying out activities involving ionising radiation to apply the principles of radiation protection and to conduct their activities in accordance with the conditions set out in the decision.
In this context, the quality and consistency of the procedures carried out at a pharmaceutical warehouse are of paramount importance.
An expert’s view
“From the perspective of a pharmaceutical wholesaler, the quality and consistency of procedures are of paramount importance. Obtaining authorisation from the President of the PAA confirms that the processes carried out at Urtica meet the formal requirements and that their implementation is overseen by an experienced team.”
Supply chain
Significance for distribution and cooperation with hospitals
In accordance with the provisions of the Atomic Energy Act, radioactive sources and radioactive waste may only be transferred in the course of activities carried out in accordance with the regulations and decisions of the competent authority.
For manufacturers, distributors, nuclear medicine centres and other healthcare organisations, this means the opportunity to work with a pharmaceutical wholesaler that is formally authorised to carry out activities relating to the storage of radioactive sources and waste.
The development of Urtica’s warehousing and logistics facilities supports the creation of a stable supply chain based on the manufacturer–warehouse–customer model, tailored to the needs of the radiopharmaceutical sector.
Regulated areas
Development of skills and infrastructure
Obtaining authorisation from the President of the National Atomic Energy Agency means that Urtica may carry out activities relating to the storage of radioactive sources and waste within the limits and under the conditions set out in the administrative decision.
The issue of such a licence is preceded by an assessment of the application and the required documentation confirming compliance with nuclear safety and radiation protection requirements.
An expert’s view
“Obtaining authorisation from the Chairman of the PAA is not merely a formality. It confirms that Urtica conducts its activities in an area requiring specific regulatory oversight in accordance with the requirements of the competent authority, in a responsible and professional manner.”
This is the result of the long-term development of our warehousing infrastructure, the expertise of our teams, and our ongoing adaptation to the requirements of the Polish pharmaceutical market and the expectations of Urtica’s business partners.
Cooperation
Radiopharmacy, storage and logistics
If you are interested in collaborating in the fields of radiopharmaceuticals, radiopharmacy, nuclear medicine, warehousing, logistics or wholesale distribution on the Polish market, please contact Urtica to discuss possible forms of collaboration.
Sources
- The Act of 29 November 2000 – Atomic Energy Act (Journal of Laws, as amended).
- Decision No. D-24586 of the President of the National Atomic Energy Agency.
- Information publications by the National Atomic Energy Agency, available on the website gov.pl/web/paa.